Drug Profile
TF 505
Alternative Names: FR-146687; TF-505Latest Information Update: 31 Mar 2010
Price :
$50
*
At a glance
- Originator Taiho Pharmaceutical
- Class
- Mechanism of Action Cholestenone 5-alpha reductase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Benign prostatic hyperplasia
Most Recent Events
- 30 Jun 2004 Phase-II clinical trials in Benign prostatic hyperplasia in Japan (PO)